<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03223272</url>
  </required_header>
  <id_info>
    <org_study_id>130822008</org_study_id>
    <nct_id>NCT03223272</nct_id>
  </id_info>
  <brief_title>Mechanisms of Refractory Hypertension (Reserpine)</brief_title>
  <official_title>Mechanisms of Refractory Hypertension (Reserpine)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Alabama at Birmingham</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is deigned to determine if refractory hypertension is attributable to heightened&#xD;
      sympathetic tone by quantifying the antihypertensive benefit of reserpine, a sympatholytic&#xD;
      agent, in patients failing other classes of antihypertensive agents.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with refractory hypertension, defined as uncontrolled office blood pressure despite&#xD;
      use of 5 or more antihypertensive agents, including a thiazide diuretic and spironolactone.&#xD;
      After withdrawal from other centrally-acting agents if needed, enrolled patients will be&#xD;
      randomized to open-label reserpine 0.1 mg daily for 4 weeks. Twenty-four hour ambulatory&#xD;
      blood pressure monitoring will be done at baseline, after the initial 4-week treatment&#xD;
      period. All other antihypertensive medications will remain unchanged during the 4-week&#xD;
      treatment period. The primary endpoint will be change in 24-hr ambulatory systolic blood&#xD;
      pressure.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 23, 2015</start_date>
  <completion_date type="Actual">January 31, 2020</completion_date>
  <primary_completion_date type="Actual">January 31, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Open-label, dose titration study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ambulatory Systolic Blood Pressure</measure>
    <time_frame>8 weeks</time_frame>
    <description>Twenty-four ambulatory systolic blood pressure</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Refractory Hypertension</condition>
  <arm_group>
    <arm_group_label>Reserpine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive open-label reserpine 0.1 mg daily for 4 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Reserpine</intervention_name>
    <description>Open label reserpine 0.1 mg pill orally</description>
    <arm_group_label>Reserpine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        - adult with refractory hypertension defined as uncontrolled office blood pressure with use&#xD;
        of 5 or more hypertensive agents, including a thiazide diuretic and spironolactone&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  congestive heart failure (EF 40%)&#xD;
&#xD;
          -  chronic kidney disease (GFR &lt;40 ml/min/1.73 mm)&#xD;
&#xD;
          -  stroke and/or myocardial infarction or acute CHF exacerbation within last 3 months&#xD;
&#xD;
          -  ongoing depression&#xD;
&#xD;
          -  active peptic ulcer disease&#xD;
&#xD;
          -  bradycardia &lt;50 beats per minute&#xD;
&#xD;
          -  2nd or 3rd degree heart block&#xD;
&#xD;
          -  known intolerance of reserpine&#xD;
&#xD;
          -  use of digoxin or tricycle antidepressants&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David A Calhoun, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UAB</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35292</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>July 17, 2017</study_first_submitted>
  <study_first_submitted_qc>July 18, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 21, 2017</study_first_posted>
  <last_update_submitted>June 10, 2020</last_update_submitted>
  <last_update_submitted_qc>June 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Alabama at Birmingham</investigator_affiliation>
    <investigator_full_name>David Calhoun</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>hypertension</keyword>
  <keyword>sympathetic tone</keyword>
  <keyword>resperpine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Reserpine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>One year after study completion, de-identified subject demographic data and primary outcome data will be available by request.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_time_frame>One year after study completion</ipd_time_frame>
    <ipd_access_criteria>By request.</ipd_access_criteria>
  </patient_data>
  <pending_results>
    <submitted>May 6, 2021</submitted>
    <returned>June 1, 2021</returned>
    <submitted>November 2, 2021</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

